Dr. Ross J. Horsburgh Brings 20 Years of Pharmaceutical and CRO Experience
in Asia/Pacific Region to Key Leadership Role
CINCINNATI, Jan. 16 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading, global full-service clinical research organization (CRO), today announced Dr. Ross J. Horsburgh has joined the company as Vice President, Global Clinical Development - Asia/Pacific. In this role, he will lead the company's overall expansion in Asia/Pacific and will provide strategic oversight for its Phase II-III operations in the region, including Melbourne and Sydney, Australia; New Delhi, India; and Beijing, China. In all, Dr. Horsburgh brings 20 years of CRO and pharmaceutical industry experience to Kendle.
"With a population base of nearly 4.0 billion and R&D spending expected to reach $20 billion by 2013, Asia/Pacific is recognized by our customers as one of the more dynamic regions in which to conduct clinical trials," said Dr. Kendle. "Dr. Horsburgh's extensive clinical development experience and familiarity with the Asia/Pacific region will benefit both our customers and Kendle as we execute on our growth strategy for this pivotal market."
Prior to joining Kendle, Dr. Horsburgh was Regional Medical Director, Asia Pacific for AstraZeneca. In this role, he assembled and led a team of 200 individuals across 13 markets. He also served as head of AstraZeneca's internal clinical research organization, responsible for quality assurance, drug safety, talent management and development, input of the Asian view into global product design, and ultimately, submissions to the U.S. Food and Drug Administration and the European Medicines Agency. Prior to AstraZeneca, Dr. Horsburgh held positions with Ciba and the Auckland Hospital Board. He earned his medical degree from the University of Auckland and his master's and bachelor's degrees from the University of Canterbury.
Dr. Horsburgh will report directly to Dr. Kendle for Asia/Pacific expansion and to Martha Feller, PhD, Senior Vice President, Global Clinical Development for Phase II-III operations. He will be based in Singapore.
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions - from first-in-human studies through market launch and surveillance - to help the world's biopharmaceutical companies maximize product life cycles and grow market share.
Our global clinical development business is focused on five regions - North America, Europe, Asia/Pacific, Latin America and Africa - to meet customer needs. We have conducted clinical trials and provided regulatory and pharmacovigilance services in more than 80 countries. The company was named the "Top CRO to Work With" in the Thomson CenterWatch 2007 Survey of U.S. Investigative Sites. Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the Company's Web site at http://www.kendle.com.
This release contains information about management's view of Kendle's future expectations, plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including, but not limited to, those set forth in the "Risk Factors" section of the company's latest Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the company's views as of the date of this press release and these views could change. However, while the company may elect to update these forward-looking statements at some point, the company specifically disclaims any obligation to do so other than as required by federal securities laws. These forward-looking statements should not be relied upon as representing the company's views as of any date subsequent to the date of this press release.
|SOURCE Kendle International Inc.|
Copyright©2008 PR Newswire.
All rights reserved